UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March 31,~~June 30, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-17999

ImmunoGen, Inc.

Massachusetts		04-2726691
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices, including zip code)

(781) 895-0600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

	Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
	Common Stock, $.01 par value		IMGN		Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ⌧ Yes ◻ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ⌧ Yes ◻ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12-b2 of the Exchange Act.

Large accelerated filer ⌧	Accelerated filer ◻
Non-accelerated filer ◻	Smaller reporting company ☐
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ⌧ No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Shares of common stock, par value $.01 per share: ~~220,536,032~~220,713,090 shares outstanding as of ~~May 2,~~July 25, 2022.

Table of Contents

IMMUNOGEN, INC.

FORM 10-Q

FOR THE QUARTER ENDED ~~MARCH 31,~~JUNE 30, 2022

TABLE OF CONTENTS



Item		Page Number		Page Number
	Part I		Part I
	Financial Information		Financial Information
1.	Financial Statements (Unaudited)	2	Financial Statements (Unaudited)	2

1a.	Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021	2	Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021	2

1b.	Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2022 and 2021	3	Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2022 and 2021	3

1c.	Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2022 and the three months ended March 31, June 30, September 30, and December 31, 2021	4	Consolidated Statements of Shareholders’ Equity for the three months ended June 30, 2022 and March 31, 2022 and the three months ended March 31, June 30, September 30, and December 31, 2021	4

1d.	Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021	5	Consolidated Statements of Cash Flows for the six months ended June 30, 2022 and 2021	5

1e.	Notes to Consolidated Financial Statements	6	Notes to Consolidated Financial Statements	6

2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

3.	Quantitative and Qualitative Disclosures about Market Risk	23	Quantitative and Qualitative Disclosures about Market Risk	23

4.	Controls and Procedures	23	Controls and Procedures	23

	Part II		Part II
	Other Information		Other Information
1A.	Risk Factors	23	Risk Factors	23

6.	Exhibits	25	Exhibits	24

	Signatures	26	Signatures	25

Forward-looking statements

This Form 10-Q includes forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, these forward-looking statements relate to analyses and other information that are based on beliefs, expectations, assumptions, and forecasts of future results and estimates of amounts that are not yet determinable. These statements also relate to our prospects, future developments, product candidates, and business strategies.

These forward-looking statements are identified by their use of terms and phrases, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms and phrases, including references to assumptions. These statements are contained in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections, as well as the notes to our financial statements and other sections of this report.

We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and investors should not place undue reliance on our forward-looking statements. Additionally, these forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from those contemplated by our forward-looking statements. These known and unknown risks, uncertainties, and other factors are described in detail in the “Risk Factors” section and in other sections of this report and our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on February 28, 2022, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, and as updated and/or supplemented in subsequent filings with the SEC. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Table of Contents

ITEM 1. Financial Statements

IMMUNOGEN, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

In thousands, except per share amounts

March 31,

December 31,

2022

2021
ASSETS

Cash and cash equivalents

$
437,661

$
478,750
Accounts receivable

1,190

4,467
Unbilled receivable

3,643

2,345
Contract assets

3,000

3,000
Non-cash royalty receivable

2,417

4,115
Prepaid and other current assets

8,807

7,322
Total current assets

456,718

499,999
Property and equipment, net of accumulated depreciation

4,431

4,663
Operating lease right-of-use assets

11,888

12,392
Other assets

8,672

8,711
Total assets

$
481,709

$
525,765
LIABILITIES AND SHAREHOLDERS’ EQUITY

Accounts payable

$
16,060

$
18,434
Accrued compensation

3,408

5,469
Other accrued liabilities

28,730

23,077
Current portion of liability related to the sale of future royalties, net of deferred financing costs of $199 and $198, respectively

8,741

6,077
Current portion of operating lease liability

3,762

3,537
Current portion of deferred revenue

23,417

44,351
Total current liabilities

84,118

100,945
Deferred revenue, net of current portion

46,694

47,717
Operating lease liability, net of current portion

14,263

15,244
Liability related to the sale of future royalties, net of current portion and deferred financing costs of $323 and $381, respectively

29,490

34,967
Other long-term liabilities

676

1,306
Total liabilities

175,241

200,179
Commitments and contingencies (Note H)

Shareholders’ equity:

Preferred stock, $.01 par value; authorized 5,000 shares; 0 shares issued and outstanding as of each of March 31, 2022 and December 31, 2021

—

—
Common stock, $.01 par value; authorized 300,000 shares; 220,536 and 220,361 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively

2,205

2,204
Additional paid-in capital

1,799,551

1,794,525
Accumulated deficit

(1,495,288)

(1,471,143)
Total shareholders’ equity

306,468

325,586
Total liabilities and shareholders’ equity

$
481,709

$
525,765


	June 30,		December 31,
	2022		2021
ASSETS
Cash and cash equivalents	$	373,874	$	478,750
Accounts receivable		909		4,467
Unbilled receivable		1,874		2,345
Contract assets		—		3,000
Non-cash royalty receivable		3,168		4,115
Prepaid and other current assets		14,099		7,322
Total current assets		393,924		499,999
Property and equipment, net of accumulated depreciation		4,334		4,663
Operating lease right-of-use assets		11,361		12,392
Other assets		12,676		8,711
Total assets	$	422,295	$	525,765
LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts payable	$	17,245	$	18,434
Accrued compensation		4,960		5,469
Other accrued liabilities		36,588		23,077
Current portion of liability related to the sale of future royalties, net of deferred financing costs of $187 and $198, respectively		8,772		6,077
Current portion of operating lease liability		3,870		3,537
Current portion of deferred revenue		15,636		44,351
Total current liabilities		87,071		100,945
Deferred revenue, net of current portion		43,611		47,717
Operating lease liability, net of current portion		13,254		15,244
Liability related to the sale of future royalties, net of current portion and deferred financing costs of $282 and $381, respectively		28,062		34,967
Other long-term liabilities		466		1,306
Total liabilities		172,464		200,179
Commitments and contingencies (Note H)
Shareholders’ equity:
Preferred stock, $.01 par value; authorized 5,000 shares; 0 shares issued and outstanding as of each of June 30, 2022 and December 31, 2021		—		—
Common stock, $.01 par value; authorized 600,000 shares; 220,644 and 220,361 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively		2,206		2,204
Additional paid-in capital		1,804,934		1,794,525
Accumulated deficit		(1,557,309)		(1,471,143)
Total shareholders’ equity		249,831		325,586
Total liabilities and shareholders’ equity	$	422,295	$	525,765

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents

IMMUNOGEN, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

In thousands, except per share amounts

Three Months Ended

March 31,

2022

2021
Revenues:

License and milestone fees

$
30,892

$
157
Non-cash royalty revenue related to the sale of future royalties

6,428

15,545
Research and development support

758

4
Total revenues

38,078

15,706
Operating expenses:

Research and development

44,282

34,413
Selling, general and administrative

16,648

10,209
Total operating expenses

60,930

44,622
Loss from operations

(22,852)

(28,916)
Investment income, net

54

13
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes

(1,249)

(4,644)
Interest expense on convertible senior notes

—

(24)
Other expense, net

(98)

(480)
Net loss

$
(24,145)

$
(34,051)
Basic and diluted net loss per common share

$
(0.10)

$
(0.17)
Basic and diluted weighted-average common shares outstanding

253,263

198,835
Total comprehensive loss

$
(24,145)

$
(34,051)



	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2022		2021		2022		2021
Revenues:
License and milestone fees	$	6,973	$	252	$	37,865	$	409
Non-cash royalty revenue related to the sale of future royalties		7,116		16,690		13,544		32,235
Research and development support		73		6		831		10
Total revenues		14,162		16,948		52,240		32,654
Operating expenses:
Research and development		51,422		34,589		95,704		69,002
Selling, general and administrative		23,793		9,728		40,441		19,937
Total operating expenses		75,215		44,317		136,145		88,939
Loss from operations		(61,053)		(27,369)		(83,905)		(56,285)
Investment income, net		590		11		644		24
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes		(1,078)		(3,557)		(2,327)		(8,201)
Interest expense on convertible senior notes		—		(23)		—		(47)
Other (expense) income, net		(480)		197		(578)		(283)
Net loss	$	(62,021)	$	(30,741)	$	(86,166)	$	(64,792)
Basic and diluted net loss per common share	$	(0.24)	$	(0.15)	$	(0.34)	$	(0.32)
Basic and diluted weighted-average common shares outstanding		253,336		199,890		253,263		199,365
Total comprehensive loss	$	(62,021)	$	(30,741)	$	(86,166)	$	(64,792)

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents

IMMUNOGEN, INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(UNAUDITED)

In thousands

Additional

Total

Common Stock

Paid-In

Accumulated

Shareholders’

Shares

Amount

Capital

Deficit

Equity
Balance at December 31, 2020

194,998

$
1,950

$
1,419,460

$
(1,331,840)

$
89,570
Net loss

(34,051)

(34,051)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan

397

4

1,282

—

1,286
Issuance of common stock, net of issuance costs

4,544

45

33,447

—

33,492
Restricted stock units vested

2

—

—

—

—
Stock option and restricted stock compensation expense

—

—

3,674

—

3,674
Directors’ deferred share unit compensation

—

—

149

—

149
Balance at March 31, 2021

199,941

$
1,999

$
1,458,012

$
(1,365,891)

$
94,120
Net loss

—

—

—

(30,741)

(30,741)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan

75

1

377

—

378
Conversion of convertible senior notes

239

3

997

—

1,000
Common stock issuance costs

—

—

(34)

(34)
Stock option and restricted stock compensation expense

—

—

3,598

—

3,598
Directors’ deferred share unit compensation

—

—

144

—

144
Balance at June 30, 2021

200,255

$
2,003

$
1,463,094

$
(1,396,632)

$
68,465
Net loss

—

—

—

(37,339)

(37,339)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan

95

1

367

—

368
Issuance of common stock, net of issuance costs

2,150

21

12,336

—

12,357
Issuance of pre-funded warrant, net of issuance costs

—

—

29,765

—

29,765
Restricted stock award forfeitures

(57)

(1)

1

—

—
Common stock issuance costs

—

—

—

—

—
Stock option and restricted stock compensation expense

—

—

3,298

—

3,298
Directors’ deferred share unit compensation

—

—

179

—

179
Balance at September 30, 2021

202,443

$
2,024

$
1,509,040

$
(1,433,971)

$
77,093
Net loss

—

—

—

(37,172)

(37,172)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan

431

4

1,733

—

1,737
Issuance of common stock, net of issuance costs

17,487

176

108,039

—

108,215
Issuance of pre-funded warrant, net of issuance costs

—

—

169,280

—

169,280
Stock option and restricted stock compensation expense

—

—

6,224

—

6,224
Directors’ deferred share unit compensation

—

—

209

—

209
Balance at December 31, 2021

220,361

$
2,204

$
1,794,525

$
(1,471,143)

$
325,586
Net loss

—

—

—

(24,145)

(24,145)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan

173

1

619

—

620
Restricted stock units vested

2

—

—

—

—
Stock option and restricted stock compensation expense

—

—

4,196

—

4,196
Directors’ deferred share unit compensation

—

—

211

—

211
Balance at March 31, 2022

220,536

$
2,205

$
1,799,551

$
(1,495,288)

$
306,468


				Additional				Total
	Common Stock			Paid-In		Accumulated		Shareholders’
	Shares	Amount		Capital		Deficit		Equity
Balance at December 31, 2020	194,998	$	1,950	$	1,419,460	$	(1,331,840)	$	89,570
Net loss							(34,051)		(34,051)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan	397		4		1,282		—		1,286
Issuance of common stock, net of issuance costs	4,544		45		33,447		—		33,492
Restricted stock units vested	2		—		—		—		—
Stock option and restricted stock compensation expense	—		—		3,674		—		3,674
Directors’ deferred share unit compensation	—		—		149		—		149
Balance at March 31, 2021	199,941	$	1,999	$	1,458,012	$	(1,365,891)	$	94,120
Net loss	—		—		—		(30,741)		(30,741)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan	75		1		377		—		378
Conversion of convertible senior notes	239		3		997		—		1,000
Common stock issuance costs	—		—		(34)				(34)
Stock option and restricted stock compensation expense	—		—		3,598		—		3,598
Directors’ deferred share unit compensation	—		—		144		—		144
Balance at June 30, 2021	200,255	$	2,003	$	1,463,094	$	(1,396,632)	$	68,465
Net loss	—		—		—		(37,339)		(37,339)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan	95		1		367		—		368
Issuance of common stock, net of issuance costs	2,150		21		12,336		—		12,357
Issuance of pre-funded warrant, net of issuance costs	—		—		29,765		—		29,765
Restricted stock award forfeitures	(57)		(1)		1		—		—
Stock option and restricted stock compensation expense	—		—		3,298		—		3,298
Directors’ deferred share unit compensation	—		—		179		—		179
Balance at September 30, 2021	202,443	$	2,024	$	1,509,040	$	(1,433,971)	$	77,093
Net loss	—		—		—		(37,172)		(37,172)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan	431		4		1,733		—		1,737
Issuance of common stock, net of issuance costs	17,487		176		108,039		—		108,215
Issuance of pre-funded warrant, net of issuance costs	—		—		169,280		—		169,280
Stock option and restricted stock compensation expense	—		—		6,224		—		6,224
Directors’ deferred share unit compensation	—		—		209		—		209
Balance at December 31, 2021	220,361	$	2,204	$	1,794,525	$	(1,471,143)	$	325,586
Net loss	—		—		—		(24,145)		(24,145)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan	173		1		619		—		620
Restricted stock units vested	2		—		—		—		—
Stock option and restricted stock compensation expense	—		—		4,196		—		4,196
Directors’ deferred share unit compensation	—		—		211		—		211
Balance at March 31, 2022	220,536	$	2,205	$	1,799,551	$	(1,495,288)	$	306,468
Net loss	—		—		—		(62,021)		(62,021)
Issuance of common stock pursuant to the exercise of stock options and employee stock purchase plan	108		1		410		—		411
Stock option and restricted stock compensation expense	—		—		4,760		—		4,760
Directors’ deferred share unit compensation	—		—		213		—		213
Balance at June 30, 2022	220,644	$	2,206	$	1,804,934	$	(1,557,309)	$	249,831

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents

IMMUNOGEN, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

In thousands

Three Months Ended

March 31,

2022

2021

Cash flows from operating activities:

Net loss

$
(24,145)

$
(34,051)
Adjustments to reconcile net loss to net cash used for operating activities:

Non-cash royalty revenue related to sale of future royalties

(2,364)

(15,545)
Non-cash interest expense on liability related to sale of future royalties and convertible senior notes

1,249

4,644
Depreciation and amortization

473

551
Stock and deferred share unit compensation

4,407

3,823
Change in operating assets and liabilities:

Accounts receivable

3,277

(58)
Unbilled receivable

(1,298)

(5,394)
Prepaid and other current assets

(1,485)

(7,520)
Operating lease right-of-use assets

504

424
Other assets

39

3,661
Accounts payable

(2,308)

3,802
Accrued compensation

(2,061)

(1,571)
Other accrued liabilities

5,023

3,487
Deferred revenue

(21,957)

(72)
Operating lease liability

(756)

(802)
Net cash used for operating activities

(41,402)

(44,621)
Cash flows from investing activities:

Purchases of property and equipment

(307)

(893)
Net cash used for investing activities

(307)

(893)
Cash flows from financing activities:

Proceeds from issuance of common stock under stock plans

620

1,286
Proceeds from common stock issuance, net of $70 of transaction costs

—

33,492
Net cash provided by financing activities

620

34,778
Net change in cash and cash equivalents

(41,089)

(10,736)
Cash and cash equivalents, beginning of period

478,750

293,856
Cash and cash equivalents, end of period

$
437,661

$
283,120




	Six Months Ended
	June 30,
	2022		2021

Cash flows from operating activities:
Net loss	$	(86,166)	$	(64,792)
Adjustments to reconcile net loss to net cash used for operating activities:
Non-cash royalty revenue related to sale of future royalties		(5,590)		(31,721)
Non-cash interest expense on liability related to sale of future royalties and convertible senior notes		2,327		8,201
Depreciation and amortization		931		1,093
Stock and deferred share unit compensation		9,380		7,565
Change in operating assets and liabilities:
Accounts receivable		3,558		28
Unbilled receivable		471		(4,216)
Contract asset		3,000		—
Prepaid and other current assets		(6,777)		(6,603)
Operating lease right-of-use assets		1,031		866
Other assets		(3,965)		2,100
Accounts payable		(1,249)		2,482
Accrued compensation		(509)		(893)
Other accrued liabilities		12,643		(146)
Deferred revenue		(32,821)		(837)
Operating lease liability		(1,657)		(1,627)
Net cash used for operating activities		(105,393)		(88,500)
Cash flows from investing activities:
Purchases of property and equipment		(514)		(940)
Net cash used for investing activities		(514)		(940)
Cash flows from financing activities:
Proceeds from issuance of common stock under stock plans		1,031		1,664
Proceeds from common stock issuance, net of $106 of transaction costs		—		33,458
Net cash provided by financing activities		1,031		35,122
Net change in cash and cash equivalents		(104,876)		(54,318)
Cash and cash equivalents, beginning of period		478,750		293,856
Cash and cash equivalents, end of period	$	373,874	$	239,538

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents

IMMUNOGEN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~March 31,~~June 30, 2022

A.	Nature of Business and Plan of Operations

ImmunoGen, Inc. (the Company) was incorporated in Massachusetts in 1981 and is focused on the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of cancer. The Company has generally incurred operating losses and negative cash flows from operations since inception, incurred a net loss of ~~$24.1~~$86.2 million during the ~~three~~six months ended ~~March 31,~~June 30, 2022, and has an accumulated deficit of approximately ~~$1.5~~$1.6 billion as of ~~March 31,~~June 30, 2022. The Company has primarily funded these losses through payments received from its collaborations and equity, convertible debt, and other financings. To date, the Company has had 0 revenues from commercial sales of its own products and management expects to continue to incur substantial operating losses for at least the near term as the Company incurs significant operating expenses related to research and development and potential commercialization of its portfolio.

As of ~~March 31,~~June 30, 2022, the Company had ~~$437.7~~$373.9 million of cash and cash equivalents on hand. The Company anticipates that its current capital resources will enable it to meet its operational expenses and capital expenditures for more than twelve months after the date these financial statements were issued. The Company ~~may~~expects to raise additional funds through equity, debt, or other financings, or generate revenues from ~~collaborators~~product sales as well as revenues from collaborations through a combination of upfront license payments, milestone payments, royalty payments, and research ~~funding.~~funding to support its planned operating activities. There can be no assurance, however, that the Company will be able to obtain additional equity, debt, or other financing or generate revenues from ~~collaborators~~product sales or from collaborations on terms acceptable to the Company or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition and require the Company to defer or limit some or all of its research, development, and/or clinical projects.

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the development by its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, manufacturing and marketing limitations, complexities associated with managing collaboration arrangements, third-party reimbursements, and compliance with governmental regulations.

B.	Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. The consolidated financial statements include all of the adjustments, consisting only of normal recurring adjustments, which management considers necessary for a fair presentation of the Company’s financial position in accordance with accounting principles generally accepted in the U.S. for interim financial information. The December 31, 2021 consolidated balance sheet presented for comparative purposes was derived from the Company’s audited financial statements, and certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. The preparation of interim financial statements requires the use of management’s estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim financial statements and the reported amounts of revenues and expenditures during the reported periods. The results of the interim periods are not necessarily indicative of the results for the entire year. Accordingly, the interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 28, 2022.

Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended ~~March 31,~~June 30, 2022 are consistent with those discussed in Note B to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Table of Contents

Revenue Recognition

Transaction Price Allocated to Future Performance Obligations

Deferred revenue under ~~ASC 606,~~Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC), Revenue from Contracts with Customers(ASC 606), represents the portion of the transaction price received under various contracts attributed to performance obligations that have not been satisfied (or have been partially ~~performed)~~satisfied) and includes unexercised contract options that are considered material rights. As of ~~March 31,~~June 30, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations comprising deferred revenue was ~~$70.1~~$59.2 million. The Company expects to recognize revenue on approximately ~~33%~~26%, ~~55%~~62%, and 12% of the remaining performance obligations over the next 12 months, 13 to 60 months, and 61 to 120 months, respectively; however, ~~it does not control when~~the timing of recognition may vary due to such factors as the amount and timing of future sales of KADCYLA, the timing of exercise of contract options considered to be material rights, or ~~if any collaborator will terminate~~termination of existing development and commercialization licenses.

Contract Balances from Contracts with Customers

The following tables present changes in the Company’s contract assets and contract liabilities during the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021 (in thousands):


	Balance at								Balance at		Balance at								Balance at
	December 31, 2021		Additions		Deductions		Impact of Netting		March 31, 2022		December 31, 2021		Additions		Deductions		Impact of Netting		June 30, 2022
Contract asset	$	3,000	$	—	$	—	$	—	$	3,000	$	3,000	$	—	$	(3,000)	$	—	$	—
Contract liabilities (deferred revenue)	$	92,068	$	3,803	$	(25,760)	$	—	$	70,111	$	92,068	$	3,803	$	(36,624)	$	—	$	59,247



	Balance at								Balance at		Balance at								Balance at
	December 31, 2020		Additions		Deductions		Impact of Netting		March 31, 2021		December 31, 2020		Additions		Deductions		Impact of Netting		June 30, 2021
Contract asset	$	—	$	0	$	—	$	—	$	—	$	—	$	0	$	—	$	—	$	—
Contract liabilities (deferred revenue)	$	110,109	$	—	$	(72)	$	—	$	110,037	$	110,109	$	—	$	(837)	$	—	$	109,272

The Company recognized the following revenues as a result of changes in contract asset and contract liability balances in the respective periods (in thousands):


	Three Months Ended				Three Months Ended				Six Months Ended
	March 31,				June 30,				June 30,
	2022		2021		2022		2021		2022		2021
Revenue recognized in the period from:
Amounts included in contract liabilities at the beginning of the period	$	25,760	$	72	$	10,864	$	765	$	36,624	$	837

Pursuant to the Company’s license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong), upon delivery of clinical materials in the ~~three~~six months ended ~~March 31,~~June 30, 2022, the Company recognized as license and milestone fee revenue ~~$21.6~~the remaining $28.5 million of the ~~$28.5 million remaining~~ deferred revenue balance as of December 31, 2021 related to the $45.0 million of upfront and development milestone payments previously received. Additionally, pursuant to a license agreement executed with Eli Lilly and Company (Lilly), during the ~~three~~six months ended ~~March 31,~~June 30, 2022, the Company received an upfront payment of $13.0 million, of which $9.2 million was recognized as license and milestone fee revenue and the remainder deferred, further details of which can be found in Note C, “Agreements.” The Company also recognized ~~$4.1~~$8.0 million of previously deferred non-cash royalty revenue related to the sale of rights to KADCYLA^® royalties, further details of which can be found in Note E, “Liability Related to Sale of Future Royalties,” and recognized ~~$0.1~~$0.2 million of license and milestone fee revenue related to numerous collaborators’ rights to technological improvements that had been previously deferred.

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, the Company recognized $0.2 million as license and milestone fee revenue for delivery of certain materials to Viridian Therapeutics that had been previously deferred and recognized $0.1 million of license and milestone fee revenue related to numerous collaborators’ rights to technological improvements that had been previously deferred.

Additionally, the Company recorded $0.5 million of previously deferred non-cash royalty

Table of Contents

revenue related to the sale of rights to KADCYLA royalties. The timing of revenue recognition, billings, and cash collections results in billed receivables, unbilled receivables, contract assets, and contract liabilities on the consolidated balance sheets. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded (under the caption deferred revenue). Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met.

Financial Instruments and Concentration of Credit Risk

Cash and cash equivalents are primarily maintained with 3 financial institutions in the U.S. Deposits with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. The Company’s cash equivalents consist of money market funds with underlying investments primarily being U.S. Government-issued securities and high quality, short-term commercial paper. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and marketable securities. The Company held 0 marketable securities as of ~~March 31,~~June 30, 2022 and December 31, 2021. The Company’s investment policy, approved by the Board of Directors, limits the amount it may invest in any one type of investment, thereby reducing credit risk concentrations.

Cash and Cash Equivalents

The Company considers all highly liquid financial instruments with maturities of three months or less when purchased to be cash equivalents. As of ~~March 31,~~June 30, 2022 and December 31, 2021, the Company held ~~$437.7~~$373.9 million and $478.8 million, respectively, in cash and money market funds, which were classified as cash and cash equivalents.

Non-cash Investing and Financing Activities

The Company had ~~$0.1~~$0.3 million and $0.2 million of accrued capital expenditures as of ~~March 31,~~June 30, 2022 and December 31, 2021, respectively, which have been treated as a non-cash investing activity and, accordingly, are not reflected in the consolidated statement of cash flows.

Fair Value of Financial Instruments

Fair value is defined under ASC 820, Fair Value Measurements and Disclosures, as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a hierarchy to measure fair value, which is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

●

Level 1 - Quoted prices in active markets for identical assets or liabilities.

●

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

●

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

~~Table of Contents~~

As of ~~March 31,~~June 30, 2022 and December 31, 2021, the Company held certain assets that are required to be measured at fair value on a recurring basis. The fair value of the Company’s cash equivalents is based on quoted prices from active markets (Level 1 inputs). The carrying amounts reflected in the consolidated balance sheets for accounts receivable, unbilled receivables, prepaid and other current assets, accounts payable, accrued compensation, and other accrued liabilities approximate fair value due to their short-term nature.

As of ~~March 31,~~June 30, 2021, the Company had outstanding convertible 4.5% senior notes (convertible notes) with a gross carrying amount and estimated fair value of ~~$2.1~~$1.1 million and ~~$5.4~~$2.3 million, respectively. The fair value of the convertible notes was influenced by interest rates, the Company’s stock price and stock price volatility, and by prices observed in trading activity for the convertible notes. Because there were 0 trades involving the convertible notes since September 2019, however, the fair value as of ~~March 31,~~June 30, 2021 used Level 3 inputs. In June 2021, $1.0 million of outstanding convertible 4.5% senior notes converted into 238,777 shares of the Company’s common stock, par value $0.01 per share ~~(common~~

Table of Contents

(common stock), with the remaining $1.1 million of convertible 4.5% senior notes paid in cash upon maturity on July 1, 2021.

Common Stock Warrants

The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance included in ~~Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC)~~ASC 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging (ASC 815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and remeasured each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss in the accompanying consolidated statements of operations and comprehensive loss.

Computation of Net Loss per Common Share

Basic and diluted net loss per share is calculated based upon the weighted average number of shares of common stock outstanding during the period. Shares of the Company’s common stock underlying pre-funded warrants are included in the calculation of basic and diluted earnings per share. During periods of income, participating securities are allocated a proportional share of income determined by dividing total weighted-average participating securities by the sum of the total weighted average common shares and participating securities (the two-class method). Shares of the Company’s restricted stock participate in any dividends that may be declared by the Company and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to participating securities since they have no contractual obligation to share in the losses of the Company. Diluted loss per share is computed after giving consideration to the dilutive effect of stock options, convertible notes, and restricted stock that are outstanding during the period, except where such non-participating securities would be anti-dilutive.

~~Table of Contents~~

The Company’s common stock equivalents, as calculated in accordance with the treasury-stock method for options and unvested restricted stock, and the if-converted method for the convertible notes, are shown in the following table (in thousands):


	Three Months Ended		Three Months Ended		Six Months Ended
	March 31,		June 30,		June 30,
	2022	2021	2022	2021	2022	2021
Options outstanding to purchase common stock, shares issuable under the employee stock purchase plan, and unvested restricted stock/units at end of period	27,012	21,320	29,528	21,681	29,528	21,681
Common stock equivalents under treasury stock method for options, shares issuable under the employee stock purchase plan, and unvested restricted stock/units	1,981	3,553	958	2,772	1,306	3,138
Shares issuable upon conversion of convertible notes at end of period	-	501
Common stock equivalents under if-converted method for convertible notes	-	501

The Company’s common stock equivalents have not been included in the net loss per share calculation because their effect is anti-dilutive due to the Company’s net loss position.

Stock-Based Compensation

As of ~~March 31,~~June 30, 2022, the Company was authorized to grant future awards under 3 employee share-based compensation plans, which are the ImmunoGen, Inc. Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan (the 2018 Plan), the Employee Stock Purchase Plan (the ESPP), and the ImmunoGen Inducement

Table of Contents

Equity Incentive Plan (the Inducement Plan). At the annual meeting of shareholders on June ~~16, 2021,~~15, 2022, the 2018 Plan was amended to provide for the issuance of stock grants, the grant of options, and the grant of stock-based awards for up to an additional ~~6,600,000~~13,000,000 shares of the Company’s common stock, as well as up to ~~22,392,986~~28,742,013 shares of common stock, which represent the number of shares of common stock remaining under the 2018 Plan as of ~~March 31, 2021,~~April 1, 2022, and awards previously granted under the 2018 Plan and the Company’s former stock-based plans, including the ImmunoGen, Inc. 2016 and 2006 Employee, Director and Consultant Equity Incentive Plans, that forfeit, expire, or cancel without delivery of shares of common stock or which resulted in the forfeiture of shares of common stock back to the Company subsequent to ~~March 31, 2021.~~April 1, 2022. The Inducement Plan was approved by the Board of Directors in December 2019, and pursuant to subsequent amendments, provides for the issuance of non-qualified option grants for up to ~~7,000,000~~10,500,000 shares of the Company’s common stock. Options awarded under the 2 plans are granted with an exercise price equal to the market price of the Company’s stock at the date of grant. Options vest at various periods of up to four years and may be exercised within ten years of the date of grant under each of these plans.

The stock-based awards are accounted for under ASC 718, “Compensation—Stock Compensation(ASC 718).” Pursuant to ASC 718, the estimated grant date fair value of awards is charged to the statement of operations over the requisite service period, which is the vesting period. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model with the weighted-average assumptions noted in the following table. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is 0. Expected volatility is based exclusively on historical volatility of the Company’s stock. The expected term of stock options granted is based exclusively on historical data and represents the period of time that stock options granted are expected to be outstanding. The expected term is calculated for and applied to one group of stock options as the Company does not expect substantially different exercise or post-vesting termination behavior among its option recipients. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options.



	Three Months Ended March 31,		Three Months Ended June 30,		Six Months Ended June 30,
	2022	2021	2022	2021	2022	2021
Dividend	NaN	NaN	NaN	NaN	NaN	NaN
Volatility	83.0%	85.4%	83.4%	84.7%	83.1%	85.3%
Risk-free interest rate	1.81%	0.62%	3.00%	1.01%	2.180%	0.67%
Expected life (years)	6.0	6.0	6.0	6.0	6.0	6.0

Using the Black-Scholes option-pricing model, the weighted-average grant date fair values of options granted during the three months ended ~~March 31,~~June 30, 2022 and 2021 were ~~$3.78~~$3.12 and ~~$5.47~~$4.92 per share, respectively, and $3.57 and $5.40 for options granted during the six months ended June 30, 2022 and 2021, respectively.

~~Table of Contents~~

A summary of option activity under the Company’s equity plans for the ~~three~~six months ended ~~March 31,~~June 30, 2022 is presented below (in thousands, except weighted-average data):


		Weighted-			Weighted-
	Number	Average		Number	Average
	of Stock	Exercise		of Stock	Exercise
	Options	Price		Options	Price
Outstanding at December 31, 2021	21,219	$	6.28	21,219	$	6.28
Granted	5,957		5.34	8,670		5.03
Exercised	(173)		3.59	(173)		3.59
Forfeited/Canceled	(66)		10.51	(263)		6.72
Outstanding at March 31, 2022	26,937	$	6.08
Outstanding at June 30, 2022				29,453	$	5.92

In 2020, the Company issued 2.6 million performance-based stock options to certain employees ~~all of which remained outstanding as of March 31, 2022,~~ that will vest upon the achievement of specified performance goals. In October 2021, upon approval by the Compensation Committee of the Company’s Board of Directors, certain terms of the performance-based stock option award agreements were modified. Pursuant to ASC 718, the Company determined the modification to be a Type IV (improbable-to-improbable) modification and revalued the modified awards as of the modification date. Upon assessment of the performance-based stock option awards as of December 31, 2021, the Company determined the first performance goal to be probable of vesting and, as such, recorded $2.6 million of stock-based compensation expense for the year ended December 31, 2021. In May 2022, the first performance goal was achieved, resulting in the vesting of 25% of the 2.6 million performance-based stock options. The ~~modification date~~ fair value of the remaining unvested performance-based stock options that could be expensed in future periods is $7.8 million.

Table of Contents

A summary of restricted stock unit activity under the Company’s equity plans for the ~~three~~six months ended ~~March 31,~~June 30, 2022 is presented below (in thousands, except weighted-average data):


	Number of	Weighted-		Number of	Weighted-
	Restricted	Average Grant		Restricted	Average Grant
	Stock Shares	Date Fair Value		Stock Shares	Date Fair Value
Unvested at December 31, 2021	77	$	5.59	77	$	5.59
Granted	-		-	-		-
Vested	(2)		2.53	(2)		2.53
Unvested at March 31, 2022	75	$	5.68
Unvested at June 30, 2022				75	$	5.68

In June 2018, the Company's Board of Directors, with shareholder approval, adopted the Employee Stock Purchase Plan (ESPP). Following the automatic share increase on January 1, 2021, pursuant to the ESPP’s “evergreen” provision, an aggregate of 2,000,000 shares of common stock have been reserved for issuance under the ESPP. ESPP purchase periods are six months and begin on January 1 and July 1 of each year, with purchase dates occurring on the final business day of the given purchase period. The fair value of each ESPP award is estimated on the first day of the offering period using the Black-Scholes option-pricing model. The Company recognizes share-based compensation expense equal to the fair value of the ESPP awards on a straight-line basis over the offering period.

Stock compensation expense related to stock options and restricted stock unit awards granted under the stock plans and the ESPP was ~~$4.2~~$4.8 million and ~~$3.7~~$9.0 million during the three and six months ended ~~March 31,~~June 30, 2022, respectively, compared to stock compensation expense of $3.6 million and $7.3 million for the three and six months ended June 30, 2021, respectively. As of ~~March 31,~~June 30, 2022, the estimated fair value of unvested employee awards, exclusive of performance awards, was ~~$46.9~~$50.1 million. The weighted-average remaining vesting period for these awards is approximately three years.

Segment Information

During all periods presented, the Company continued to operate in 1 reportable business segment under the management approach of ASC 280, Segment Reporting, which is the business of the discovery and development of ADCs for the treatment of cancer.

~~Table of Contents~~

During the three months ended ~~March 31,~~June 30, 2022, Roche and ~~2021, 17% and~~Huadong each represented 50% of revenue, compared to 99%~~, respectively,~~ of ~~revenues were~~revenue from Roche ~~consisting primarily of non-cash royalty revenue. During~~during the three months ended ~~March 31,~~June 30, 2021. During the six months ended June 30, 2022, ~~59%~~56%, 26%, and ~~24%~~17% of revenues were from Huadong, Roche, and Lilly, ~~respectively.~~respectively, compared to 99% of revenue from Roche in the six months ended June 30, 2021. Revenue from Roche in all periods consisted of non-cash royalty revenue. There were 0 other customers of the Company that generated significant revenues in the three and six months ended ~~March 31,~~June 30, 2022 and 2021.

Recently Adopted Accounting Pronouncements

There were no recently issued or effective ~~ASUs~~FASB Accounting Standards Updates (ASUs) that had, or are expected to have, a material effect on the Company's results of operations, financial condition, or liquidity.

C.Agreements

Significant Collaborative Agreements

Lilly

In February 2022, the Company entered into a license agreement with Eli Lilly and Company (Lilly), pursuant to which the Company granted Lilly worldwide exclusive rights to research, develop, and commercialize antibody-drug conjugates based on the Company’s novel camptothecin technology. Under the terms of the license agreement, the Company received a non-refundable upfront payment of $13.0 million, reflecting initial targets selected by Lilly. Lilly may select a pre-specified number of additional targets, with the Company eligible to receive an additional $32.5 million in exercise fees if Lilly licensesthe full number of additional targets over the four year period following the effective date of the license agreement, with the potential for up to $1.7 billion in development and sales-based milestone payments if all targets are selected and all milestones are realized. In addition, the Company is entitled to receive tiered royalties, on a product-by-product basis, as a percentage of worldwide annual net sales by Lilly, based on certain net sales thresholds.

Table of Contents

Lilly is responsible for all costs associated with the research, development, and commercialization of any ensuing products.

The Company evaluated the agreement and determined it was within the scope of ASC 606. The Company determined the promised goods and services included an exclusive license to use the Company’s intellectual property and know-how to research, develop, and commercialize products related to each of the initial targets selected by Lilly. Each of these licenses is distinct, as Lilly can derive benefit from each license independent of any other initial target licenses. Accordingly, the license to each of the initial targets selected by Lilly represents a separate performance obligation. Lilly has the right to replace each of the initial licensed targets once during a specified term for no additional consideration. If Lilly fails to advance an initial or replacement target to a specified stage within a specified period from the date the target was selected, Lilly’s rights to the respective target will cease and will revert back to the Company. The Company determined Lilly’s right to a replacement target for each of the initial targets represented a material right. Each material right is therefore a separate performance obligation.

Lilly’s right to select additional targets does not represent a material right as the target fee for each additional target is the same and is also consistent with the target fee for each of the initial targets selected by Lilly. Accordingly, each additional target selected by Lilly, if any, will be accounted for as a separate arrangement.

The transaction price was determined to consist of the upfront payment of $13.0 million. Future development milestones have been fully constrained. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Lilly. The transaction price of $13.0 million was allocated to the performance obligations based on their relative stand-alone selling prices. In consideration of each target being at the same stage of development at the time of the initial license or at the time of replacement and each target having approximately the same earnings potential, the Company allocated the $13.0 million transaction price equally across the initial target licenses and the corresponding material rights to obtain licenses to replacement targets, adjusted based on the probability that Lilly would exercise those rights. The Company considered pharmaceutical industry data of the probability of early-stage assets to advance to clinical stage in determining the probability that Lilly would exercise its option to a replacement target. Accordingly, $9.2 million and $3.8 million of the total transaction price was allocated to the initial targets and the material rights to obtain licenses to replacement targets, respectively. The Company re-evaluates the transaction price, including its estimated variable

~~Table of Contents~~

consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur.

Upon completion of the transfer of intellectual property and know-how to Lilly during the ~~quarter~~six months ended ~~March 31,~~June 30, 2022, the Company recognized $9.2 million of license and milestone fee revenue related to the portion of the transaction price allocated to the initial target licenses. The $3.8 million allocated to the material rights to obtain licenses to replacement targets is included in long-term deferred revenue as of ~~March 31,~~June 30, 2022 and will be recognized when the right is either exercised or expires.

Roche

In 2000, the Company granted Genentech, now a unit of Roche, an exclusive development and commercialization license to use the Company’s maytansinoid ADC technology. Pursuant to this agreement, Roche developed and received marketing approval for its HER2-targeting ADC, KADCYLA, in the U.S., Japan, the European Union, and numerous other countries. In accordance with the Company’s revenue recognition policy, ~~$6.4~~$13.5 million and ~~$15.5~~$32.2 million of non-cash royalties on net sales of KADCYLA were recognized and included in non-cash royalty revenue for the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021, respectively. The Company sold its rights to receive royalty payments on the net sales of KADCYLA through two separate transactions in 2015 and 2019. Following the 2019 transaction, OMERS, the defined benefit pension plan for municipal employees in the Province of Ontario, Canada, is entitled to receive all of these royalties.

Huadong

In October 2020, the Company entered into a collaboration and license agreement with Huadong. The collaboration and license agreement grants Huadong an exclusive, royalty-bearing, and sublicensable right to develop and commercialize mirvetuximab soravtansine (the Licensed Product) in the People’s Republic of China, Hong Kong, Macau, and Taiwan (collectively, Greater China). The Company retains exclusive rights to the Licensed Product outside of Greater China. Under the terms of the collaboration and license agreement, the Company received a non-refundable

Table of Contents

upfront payment of $40.0 million with the potential for approximately $265.0 million in development, regulatory, and sales-based milestone payments.

In December 2021, the Company received a $5.0 million payment upon achievement of a development milestone.

The Company determined that revenue related to the agreement would be recognized as the clinical supply of the Licensed Product is delivered to Huadong, estimated to be completed over approximately two years. Accordingly, based on clinical supply delivered to Huadong induring the ~~three~~six months ended ~~March 31,~~June 30, 2022, the Company recorded ~~$21.6~~the remaining $28.5 million of the ~~$28.5 million remaining~~ deferred revenue balance as of December 31, 2021 related to the $45.0 million of upfront and development milestone payments previously received. ~~As of March 31, 2022, total deferred revenue related to the Huadong arrangement was $6.9 million and is expected to be recognized during 2022 as additional clinical supply is delivered.~~

Viridian

In October 2020, the Company entered into a license agreement with Viridian Therapeutics, Inc. pursuant to which the Company granted Viridian the exclusive right to develop and commercialize an insulin-like growth factor-1 receptor (IGF-1R) antibody for all non-oncology indications that do not use radiopharmaceuticals in exchange for an upfront payment, with the potential to receive up to a total of $143.0 million in development, regulatory, and sales-based milestone payments plus royalties on the commercial sales of any resulting product. In the three months ended December 31, 2021, a $3.0 million development milestone became probable of being achieved, which was allocated to the previously delivered license and recognized as revenue as a component of license and milestone fees for the three months ended December 31, 2021. The development milestone was subsequently achieved in April 2022.

For additional information related to these agreements, as well as the Company’s other significant collaborative agreements, please read Note C, “Agreements - Significant Collaborative Agreements,” to the audited financial statements included within the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 28, 2022.

~~Table of Contents~~

D.	Liability Related to Sale of Future Royalties

In 2015, Immunity Royalty Holdings, L.P. (IRH) purchased the right to receive 100% of the royalty payments on commercial sales of KADCYLA arising under the Company’s development and commercialization license with Genentech, until IRH had received aggregate royalties equal to $235.0 million or $260.0 million, depending on when the aggregate royalties received by IRH reach a specified milestone. Once the applicable threshold was met, the Company would thereafter have received 85% and IRH would have received 15% of the KADCYLA royalties for the remaining royalty term. At the consummation of the transaction, the Company received cash proceeds of $200 million. As part of this sale, the Company incurred $5.9 million of transaction costs, which are presented net of the liability in the accompanying consolidated balance sheet and are being amortized to interest expense over the estimated life of the royalty purchase agreement. Although the Company sold its rights to receive royalties from the sales of KADCYLA, as a result of its then ongoing involvement in the cash flows related to these royalties, the Company continues to account for these royalties as revenue and recorded the $200.0 million in proceeds from this transaction as a liability related to sale of future royalties (Royalty Obligation) that is being amortized using the interest method over the estimated life of the royalty purchase agreement.

In January 2019, the Company sold its residual rights to receive royalty payments on commercial sales of KADCYLA to OMERS for a payment of $65.2 million (amount is net of $1.5 million in broker fees). Simultaneously, OMERS purchased IRH’s right to the royalties the Company previously sold to IRH as described above, therefore obtaining the rights to 100% of the royalties received from that date on. Because the Company will not be involved with the cash flows related to the residual royalties, the $65.2 million of net proceeds received from the sale of its residual rights to receive royalty payments was recorded as deferred revenue and will be amortized as the royalty revenue related to the residual rights is earned using the units of revenue approach. During the second quarter of 2021, the aggregate royalty threshold was met and, in accordance with the Company’s revenue recognition policy, ~~$4.1~~$8.0 million and $0.5 million of revenue related to the residual rights was recognized and is included in non-cash royalty revenue for the ~~three~~six months ended ~~March 31, 2022.~~June 30, 2022 and 2021, respectively. Additionally, the purchase of IRH’s interest by OMERS did not result in an extinguishment or modification of the original instrument and, accordingly, the Company continues to account for the remaining obligation as a liability as outlined above.

Table of Contents

The following table shows the activity within the liability account during the ~~three-month~~six-month period ended ~~March 31,~~June 30, 2022 (in thousands):



	Three Months Ended		Six Months Ended
	March 31, 2022		June 30, 2022
Liability related to sale of future royalties, net — beginning balance	$	41,044	$	41,044
Proceeds from sale of future royalties, net		—		—
KADCYLA royalty payments received and paid		(4,062)		(6,537)
Non-cash interest expense recognized		1,249		2,327
Liability related to sale of future royalties, net — ending balance	$	38,231	$	36,834

The Company receives royalty reports and royalty payments related to sales of KADCYLA from Roche one quarter in arrears. As royalties are remitted to OMERS, the balance of the Royalty Obligation will be effectively repaid over the life of the agreement. In order to determine the amortization of the Royalty Obligation, the Company is required to estimate the total amount of future royalty payments to be received and remitted as noted above over the life of the agreement. The sum of these amounts less the $200 million proceeds the Company received from IRH will be recorded as interest expense over the life of the Royalty Obligation. Since inception, the Company’s estimate of this total interest expense has resulted in an imputed annual interest rate of 10.5%, and a current imputed interest rate of ~~11.5%~~10.6% as of ~~March 31,~~June 30, 2022. The Company periodically assesses the estimated royalty payments to IRH/OMERS, and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the Royalty Obligation. There are a number of factors that could materially affect the amount and timing of royalty payments from Genentech, most of which are not within the Company’s control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, patent protection, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties are paid in U.S. dollars (USD) while significant portions of the underlying sales of KADCYLA are made in currencies other than USD, and other events or circumstances that could result in reduced royalty

~~Table of Contents~~

payments from KADCYLA, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Obligation. Conversely, if sales of KADCYLA are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by the Company would be greater over the term of the Royalty Obligation.

E.	Income Taxes

As part of the Tax Cuts and Jobs Act of 2017 (TCJA), beginning with the 2022 tax year, the Company is required to capitalize research and development expenses, as defined under Internal Revenue Code section 174. For expenses that are incurred for research and development in the U.S., the amounts will be amortized over 5 years, and expenses that are incurred for research and experimentation outside the U.S. will be amortized over 15 years. The Company expects that this provision will result in a significant decrease to its 2022 tax loss, but will not result in an actual tax liability for 2022.

During the three and six months ended June 30, 2022, the Company transferred certain of its intellectual property rights to a newly formed Swiss subsidiary. This transfer resulted in a significant income inclusion for U.S. tax purposes which has been completely offset by utilization of a portion of the Company’s net operating loss carryforwards that existed before the transaction, resulting in no income tax.

F.	Capital Stock

Pre-Funded ~~Warrant~~Warrants

On August 11, 2021, the Company entered into a Securities Purchase Agreement (SPA) with RA Capital Healthcare Fund, L.P. (RA Capital), pursuant to which the Company agreed to sell to RA Capital a pre-funded warrant to purchase up to an aggregate of 5,434,782 shares of the Company’s common stock for $5.51 per share of common stock underlying the pre-funded warrant. The per share exercise price of the pre-funded warrant is $0.01. The private placement resulted in aggregate net proceeds of $29.7 million.

In connection with a public offering in December 2021, the Company issued pre-funded warrants to purchase up to an aggregate of 16,000,000 and 11,363,636 shares of the Company’s common stock to RA Capital and Redmile Group,

Table of Contents

LLC, respectively, for $6.59 per share of common stock underlying the pre-funded warrants, which, together with the per share exercise price of $0.01, is equal to $6.60, the public offering price of the shares of common stock in the public offering, which resulted in aggregate net proceeds of $169.3 million. RA Capital and Redmile Group, LLC are each considered related parties pursuant to ASC 850, Related Party Disclosures.

The pre-funded warrants’ fundamental transaction provision does not provide the warrant holders with the option to settle any unexercised warrants for cash in the event of any fundamental transactions; rather, in all fundamental transaction scenarios, the warrant holder will only be entitled to receive from the Company or any successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the shareholders of the Company in connection with the fundamental transaction, whether that consideration be in the form of cash, stock or any combination thereof. The pre-funded warrants also include a separate provision whereby the exercisability of the warrants may be limited if, upon exercise, the warrant holder or any of its affiliates would beneficially own more than 9.99% of the Company’s common stock. This threshold is subject to the holder’s rights under the pre-funded warrants to increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days’ prior notice from the holder to the Company.

The Company assessed the pre-funded warrants for appropriate equity or liability classification pursuant to the Company’s accounting policy described in Note B, “Summary of Significant Accounting Policies.” During this assessment, the Company determined the pre-funded warrants are freestanding instruments that do not meet the definition of a liability pursuant to ASC 480 and do not meet the definition of a derivative pursuant to ASC 815. The pre-funded warrants are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Based on the results of this assessment, the Company concluded that the pre-funded warrants are freestanding equity-linked financial instruments that meet the criteria for equity classification under ASC 480 and ASC 815. Accordingly, the pre-funded warrants were classified as equity and accounted for as a component of additional paid-in capital at the time of issuance and at each subsequent balance sheet date. The Company also determined that the pre-funded warrants should be included in the determination of basic and diluted earnings per share in accordance with ASC 260, Earnings per Share.

Compensation Policy for Non-Employee Directors

Pursuant to the Compensation Policy for Non-Employee Directors, as amended, non-employee directors are granted deferred share units upon initial election to the Board of Directors and annually thereafter. Initial awards and annual retainers vest quarterly over approximately three years and one year from the date of grant, respectively,

~~Table of Contents~~

contingent upon the individual remaining a director of ImmunoGen as of each vesting date. The number of deferred share units awarded is fixed per the policy on the date of the award. All unvested deferred share units will automatically vest immediately prior to the occurrence of a change of control. The redemption amount of deferred share units issued will be paid in shares of common stock of the Company on the date a director ceases to be a member of the Board of Directors.

Pursuant to the Compensation Policy for Non-Employee Directors, as amended, non-employee directors also receive stock option awards upon initial election to the Board of Directors and annually thereafter. The directors received a total of ~~352,000~~approximately 322,000 and ~~300,000~~352,000 options in ~~2021~~2022 and ~~2020,~~2021, respectively, and the related compensation expense for the three and six months ended ~~March 31,~~June 30, 2022 and 2021 is included in the amounts discussed in the “Stock-Based Compensation” section of Note B above.

G.	Leases

The Company currently has one real estate lease ~~with CRP/King 830 Winter L.L.C.~~ for the rental of approximately 120,000 square feet of laboratory and office space at 830 Winter Street, Waltham, Massachusetts through March 2026. The Company uses this space for its corporate headquarters and other operations. The Company may extend the lease for 2 additional terms of five years and is required to pay certain operating expenses for the leased premises subject to escalation charges for certain expense increases over a base amount. DuringIn 2020, the Company executed 4 subleases for approximately 65,000 square feet of this space in the aggregate through the remaining initial term of the lease. ~~The balance of~~During the ~~space is being used by the Company.~~

The Company’s operating lease liabilities related to its real estate lease agreements were calculated using a collateralized incremental borrowing rate. The weighted average discount rate for the operating lease liability is approximately 11%. A 100 basis point change in the incremental borrowing rate would result in less than a $1 million impact to the ROU assets and liabilities recorded. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term, which was $1.0 million in each of the three-month periods ended March 31, 2022 and 2021 and is included in operating expenses in the consolidated statement of operations. Cash paid against operating lease liabilities was $1.2 million and $1.4 million in the three-month periods ended March 31, 2022 and 2021, respectively. As of March 31, 2022, the Company’s ROU asset and lease liability for operating leases totaled $11.9 million and $18.0 million, respectively, and the weighted-average remaining term of the operating leases is approximately four years.

~~The maturities of operating lease liabilities discussed above are as follows (in thousands):~~

2022 (nine months remaining)

$
4,114
2023

5,503
2024

5,522
2025

5,543
2026

1,429
Thereafter

13
Total lease payments

22,124
Less imputed interest

(4,099)
Total lease liabilities

$
18,025

In addition to the amounts in the table above, the Company is also responsible for variable operating expenses and real estate taxes that are expected to approximate $3.4 million per year through March 2026.

~~Sublease Income~~

In 2020, the Company executed 4 agreements to sublease a total of approximately 65,000 square feet of the Company’s leased space at 830 Winter Street, Waltham, Massachusetts through March 2026. During each of the threesix months ended ~~March 31,~~June 30, 2022 and 2021, the Company recorded ~~$1.2~~sublease income of $2.2 million ~~of sublease income,~~and $2.4 million, respectively, inclusive of the sublessees’ proportionate share of operating expenses and real estate taxes for the period. Except as disclosed below, there have been no material changes in lease obligations from those disclosed in Note J, “Leases,” to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

~~Two~~In June 2022, in order to reclaim laboratory and office space, the Company modified one of ~~the four~~its sublease agreements ~~include~~to terminate the sublease early, targeting an ~~early termination option after certain periods~~end date of ~~time for an agreed-upon fee. Assuming no early termination option is exercised,~~March 31, 2023. Pursuant to the amended sublease agreement, the Company is ~~entitled~~required to ~~receive $12.5~~pay the sublessee $3.5 million ~~in minimum rental payments over the remaining term~~as a lease incentive, of ~~the subleases,~~ which ~~is not included in the operating lease liability table above. The sublessees are also responsible for their proportionate share of variable operating expenses and real estate taxes.~~$1.8 million was paid

1615

Table of Contents

in June 2022 and the remainder will be paid at the end of the sublease term. No other terms from the original sublease agreement were modified. In accordance with ASC 842, Leases, the $3.5 million lease incentive is being recognized on a straight-line basis over the remaining sublease term. As a result of the early termination, the Company will forego $2.1 million in minimum future rental payments. The Company assessed the underlying right-of-use asset and determined there was 0 impairment.

H. Commitments and Contingencies

Research Collaboration Agreement

In June 2022, the Company entered into a research collaboration agreement with Oxford BioTherapeutics Ltd (OBT) to develop novel ADCs utilizing the Company’s linker-payload technology directed to targets identified via OBT's proprietary OGAP® discovery platform. Under the terms of the agreement, OBT received a non-refundable $7.5 million upfront payment reflecting OBT's preclinical programs to be included in the collaboration. Additionally, over the initial three-year term of the agreement, the Company is committed to reimbursing OBT up to $2.8 million annually to support research activities dependent on the number of active programs. Otherwise, each party is responsible for its own costs associated with the joint research plan. After antibodies generated by OBT have been conjugated with the Company's proprietary linker-payload technology, each party will have the opportunity to select one or more development programs to further develop on its own. Each party will be eligible to receive milestone payments based on the achievement of pre-specified development and regulatory milestones, as well as tiered royalties as a percentage of worldwide commercial sales, with respect to each program selected by the other party. Once a party has selected a given program, it will be solely responsible for all research and development costs associated with that specific program. If at the end of the initial three-year term, either party elects not to extend the research term, predetermined opt-out fees may apply based on the number of programs selected for further development by each party. At any time starting twelve months after the effective date of the agreement, the Company may terminate the agreement in its sole discretion upon 90 days written notice to OBT. Otherwise, the agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions.

In accordance with ASC 730, Research and Development, the $7.5 million upfront payment made to OBT was expensed as incurred and is included in research and development expense for the three and six months ended June 30, 2022. The committed reimbursement to OBT and other research costs will be expensed as incurred over the research term.

Manufacturing Commitments

As of ~~March 31,~~June 30, 2022, the Company had noncancelable obligations under several agreements related to in-process and future manufacturing of antibody, drug substance, and cytotoxic agents required for supply of the Company’s product candidates totaling ~~$18.3~~$13.0 million. Additionally, pursuant to commercial agreements for future production of antibody, our noncancelable commitments total ~~$53.9~~$45.1 million at ~~March 31,~~June 30, 2022.

Litigation

The Company is not a party to any material litigation.

I.Related Party Transactions

The Company’s chief executive officer has served as a director on the ~~Board~~board of directors of Ergomed PLC since June 2021. During the ~~three~~six months ended ~~March 31,~~June 30, 2022, the Company executed agreements with Ergomed Clinical Research, Inc. and PrimeVigilance USA, Inc., subsidiaries of Ergomed PLC, for clinical trial and pharmacovigilance-related services. Ergomed Clinical Research, Inc. and PrimeVigilance USA, Inc. are each considered related parties pursuant to ASC 850, Related Party Disclosures. ~~Expenses recorded related~~In the six months ended June 30, 2022, the Company made payments totaling $3.0 million to ~~these agreements~~Ergomed Clinical Research, Inc. Payments made pursuant to the agreement with PrimeVigilance USA, Inc. during the ~~three~~six months ended ~~March 31,~~June 30, 2022 were not material to the Company’s consolidated statement of operations.

J.Subsequent Events

The Company has evaluated all events or transactions that occurred after ~~March 31,~~June 30, 2022, up through the date the Company issued these financial statements. In April 2022, a development milestone pursuant to the Company’s license agreement with Viridian was achieved, triggering a $3.0 million payment to the Company. The revenue related to this milestone was recorded in 2021 when it was determined to be probable of being achieved. The Company did not have any ~~other~~ material subsequent events.

Table of Contents

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following information should be read in conjunction with the unaudited financial statements and the notes thereto included elsewhere in this report, and the consolidated financial statements and notes thereto for the year ended December 31, 2021, and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the United States Securities and Exchange Commission, or the SEC, on February 28, 2022.

OVERVIEW

We are a clinical-stage biotechnology company focused on developing and commercializing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer patients more good days. We call this our commitment to “target a better now.”

An ADC with our proprietary technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of our potent anti-cancer agents as a “payload” to kill the tumor cell once the ADC has bound to its target. ADCs are an expanding approach to the treatment of cancer, with ~~eleven~~twelve approved products and the number of agents in development growing significantly in recent years.

We have established a leadership position in ADCs with a portfolio of differentiated product candidates to address both solid tumors and hematological malignancies.

Our business

Our lead program is mirvetuximab soravtansine (MIRV), a first-in-class investigational ADC targeting FRα, a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Following consultation with the FDA, we initiated two trials of MIRV in patients with platinum-resistant ovarian cancer whose tumors express high levels of FRα: SORAYA, a single-arm clinical trial that could lead to accelerated approval, pending FDA review; and MIRASOL, a randomized Phase 3 clinical trial that, if successful, could lead to full approval in this setting. In November 2021, we reported positive top-line data from SORAYA with an

~~Table of Contents~~

overall response rate (ORR) by investigator of 32.4%. At the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting in March 2022, we reported the full data set from SORAYA, including the median duration of response of 6.9 months. In March 2022, we submitted a biologics license application (BLA) to the FDA for accelerated approval of MIRV in second through fourth-line patients with FRα-positive, platinum-resistant ovarian cancer.The FDA accepted the BLA under Priority Review designation in May 2022 and set a Prescription Drug User Fee Act (PDUFA) action date of November 28, 2022. In June 2022, we presented additional efficacy and safety analyses from the MIRV program at the American Society of Clinical Oncology and in July, we completed enrollment in MIRASOL and expect to report top-line data from this study in early 2023.

Beyond platinum-resistant ovarian cancer, our strategy is to move MIRV into platinum-sensitive disease and become the combination agent of choice in ovarian cancer. To this end, we initiated PICCOLO, a single-arm study of MIRV monotherapy in later-line platinum-sensitive patients. We have also generated encouraging data in recurrent platinum-sensitive disease with the combination of MIRV plus carboplatin and are supporting investigator sponsored trials (ISTs) with this combination in a single-arm study in the neoadjuvant setting and in a randomized study comparing MIRV combined with carboplatin to standard of care in patients with recurrent platinum-sensitive disease. We are also ~~intend to initiate~~initiating a single-arm Phase 2 study (0420) of this combination followed by MIRV continuation in FRα-low, medium, and high patients with platinum-sensitive disease. Results from this study and our ongoing ISTs will inform a path to the potential registration for MIRV plus carboplatin and, in parallel, could support compendia listing for this combination.

In addition, we ~~presentedmature~~have generated datafrom our Phase 1b FORWARD II trial of MIRV plus AVASTIN^® (bevacizumab) in recurrent ovarian cancer ~~in an oral presentation at the American Society for Clinical OncologyAnnualMeeting~~in~~June2021~~ and believe ~~the~~these data could support compendia listing for this combination in close proximity to the initial monotherapy approval of MIRV. ~~Furthermore, we recently~~We also aligned with the FDA on GLORIOSA, a randomized Phase 3 study of MIRV plus bevacizumab maintenance in FRα-high recurrent platinum-sensitive ~~disease. We expect to initiate~~disease, and have initiated this potentially label-enabling ~~study in mid-2022.~~study.

Pivekimab sunirine (PVEK), formerly known as IMGN632, is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the novel IGN(indolinobenzodiazepine pseudodimer) class. Our IGNs are designed to alkylate DNA without cross-linking, which has

Table of Contents

provided a broad therapeutic index in preclinical models. We are advancing PVEK in clinical trials for patients with ~~BPDCN~~blastic plasmacytoid dendritic cell neoplasm (BPDCN) and ~~AML.~~acute myeloid leukemia (AML).

BPDCN is a rare form of blood cancer, with an annual incidence of between 500 and 1,000 patients in the US. In October 2020, the FDA granted Breakthrough Therapy designation for PVEK for the treatment of patients with relapsed or refractory BPDCN. Based on feedback from the FDA, we amended our ongoing 801 Phase 2 study, known as CADENZA, to include a new cohort of up to 20 frontline BPDCN patients. We now expect to generate top-line data for this frontline cohort inbefore the ~~second half~~end of 2022.

We are also conducting our 802 study for PVEK, which is a Phase 1b/2 study designed to determine the safety, tolerability, and preliminary antileukemia activity of PVEK when administered in combination with azacytidine and venetoclax to patients with relapsed and frontline CD123-positive AML. Having identified the recommended phase 2 dose for the triplet, patients are accruing in both expansion cohorts and we expect to share initial data from these cohorts at the American Society of Hematology Annual Meeting later this year.

In addition, we are advancing our earlier-stage pipeline programs. IMGC936 is an ADC in co-development with MacroGenics, Inc. that is designed to target ADAM9, an enzyme over-expressed in a range of solid tumors and implicated in tumor progression and metastasis. IMGC936 incorporates a number of innovations, including antibody engineering to extend half-life, site-specific conjugation with a fixed drug-antibody ratio to enable higher dosing, and a next-generation linker and payload designed for improved stability and bystander activity. We continue to enroll patients in the Phase 1 study for this program and expect initial data in 2022.

IMGN151 is our next generation anti-FRα product candidate in development. This ADC integrates innovation in each of its components, which we believe may enable IMGN151 to address patient populations with lower levels of FRα expression, including tumor types outside of ovarian cancer. In January 2022, we submitted an IND application to evaluate IMGN151 in a planned Phase 1 clinical trial in patients with recurrent endometrial cancer and recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers. In February 2022, the FDA placed a hold on our IND application pending responses to certain chemistry, manufacturing, and controls, or CMC, information requests. We are generating data responsive to these requests and anticipate enrolling our first patient following submission of this information to the agency.

We have selectively licensed restricted access to our ADC platform technology to other companies to expand the use of our technology and to provide us with cash to fund our own product programs. These agreements typically provide the licensee with rights to use our ADC platform technology with its antibodies or related targeting vehicles to a defined

~~Table of Contents~~

target to develop products. The licensee is generally responsible for the development, clinical testing, manufacturing, registration, and commercialization of any resulting product candidate. As part of these agreements, we are generally entitled to receive upfront fees, potential milestone payments, and royalties on the sales of any resulting products.

In February 2022, we entered into a license agreement with Eli Lilly and Company (Lilly), pursuant to which the Company granted Lilly worldwide exclusive rights to research, develop, and commercialize ~~antibody-drug conjugates~~ADCs based on the Company’s novel camptothecin technology. ~~Under the terms of the license agreement, the Company received~~Additionally, in June 2022, we entered into a non-refundable upfront payment of $13.0 million, reflecting initial targets selected by Lilly. Lilly may select a pre-specified number of additional targets, with the Company eligible to receive an additional $32.5 million in exercise fees if Lilly licenses the full number of additional targets over the four year period following the effective date of the licenseresearch collaboration agreement with Oxford BioTherapeutics Ltd (OBT) to develop novel ADCs utilizing the ~~potential for up~~Company’s linker-payload technology directed to ~~$1.7 billion in~~targets identified via OBT's proprietary OGAP® discovery platform. After antibodies generated by OBT have been conjugated with ImmunoGen's proprietary linker-payload technology, each company will have the opportunity to select one or more development ~~and sales-based milestone payments if all targets are selected and all milestones are realized. In addition, the Company is entitled~~programs to ~~receive tiered royalties,~~further develop on ~~a product-by-product basis, as a percentage of worldwide annual net sales by Lilly, based on certain net sales thresholds.~~its own. For more information concerning these relationships, including their ongoing financial and accounting impact on our business, please read Note C, “Significant Collaborative Agreements,” and Note H, “Commitments and Contingencies,” to our consolidated financial statements included in this report.

To date, we have not generated revenues from commercial sales of internal products, and we expect to continue to incur significant operating expenses related to research and development and the potential commercialization of our portfolio over the next several years. As of ~~March 31,~~June 30, 2022, we had ~~$437.7~~$373.9 million in cash and cash equivalents compared to $478.8 million as of December 31, 2021.

Managing the impact of the COVID-19 pandemic

Since the first quarter of 2020, we have continued to move our clinical studies forward while adapting to meet the evolving challenges of the COVID-19 pandemic. We implemented business continuity plans in March 2020 that enabled our workforce to remain productive while working from home until mid-September 2021, at which time our

Table of Contents

workforce returned to the office. From a manufacturing and supply chain perspective, we believe we have sufficient inventory on hand for all of our ongoing and near-term studies and to support the launch of MIRV, if approved. From a regulatory perspective, since the beginning of the pandemic, we have received timely reviews of our submissions to the FDA and other health authorities covering our clinical trial ~~applications.~~applications, as well as timely acceptance by the FDA of our BLA submitted in March 2022 for accelerated approval of MIRV.

The impact of COVID-19 slowed site activation and patient enrollment for both SORAYA and MIRASOL, which resulted in a limited delay in patient accrual for each of these studies. COVID-19 related conditions may also affect accrual of our currently-enrolling studies.

Critical accounting policies and estimates

We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.

We believe that our application of the following accounting policies, each of which requires significant judgments and estimates on the part of management, are the most critical to aid in fully understanding and evaluating our reported financial results:

●

revenue recognition;

●

clinical trial accruals; and

●

stock-based compensation.

During the three and six months ended ~~March 31,~~June 30, 2022, there were no material changes to our critical accounting policies and estimates as reported in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022.

~~Table of Contents~~

RESULTS OF OPERATIONS

Revenues

For the three months ended ~~March 31,~~June 30, 2022, our total revenues decreased $2.8 million compared to the three months ended June 30, 2021, driven by lower non-cash royalty revenue, partially offset by an increase in license and milestone fees. For the six months ended June 30, 2022, our total revenues increased ~~to $38.1~~$19.6 million compared to ~~$15.7 million for~~ the ~~three~~six months ended ~~March 31,~~June 30, 2021, driven by an increase in license and milestone fees, partially offset by lower non-cash royalty ~~revenue, both of which are discussed~~revenue. See further discussion below.

License and milestone fees

The amount of license and milestone fees we earn is directly related to the number of our collaborators, the advancement of product candidates covered by the agreements with our collaborators, and the overall success in the clinical trials of these product candidates. As such, the amount of license and milestone fees recognized may vary significantly from quarter to quarter and year to year. License and milestone fee revenue increased ~~$30.7~~$6.7 million and $37.5 million in the three and six months ended ~~March 31,~~June 30, 2022, respectively, compared to the three and six months ended ~~March 31,~~June 30, 2021. Driving the ~~increase,~~increases, pursuant to our license agreement with Huadong executed in October 2020, upon delivery of clinical supply in the three and six months ended ~~March 31,~~June 30, 2022, we recognized ~~$21.6~~$6.9 million and $28.5 million of the ~~$28.5 million~~ remaining deferred revenue balance as of December 31, 2021 related to upfront and development milestone payments previously received. Additionally, pursuant to a license agreement with Lilly, ~~executed~~ during the ~~three~~six months ended ~~March 31,~~June 30, 2022, we recognized $9.2 million of the $13.0 million upfront payment received.

Table of Contents

Non-cash royalty revenue related to the sale of future royalties

KADCYLA is a marketed ADC resulting from one of our development and commercialization licenses with Roche, through its Genentech unit. We receive royalty reports and payments related to sales of KADCYLA from Roche one quarter in arrears. We sold our rights to receive royalty payments on the net sales of KADCYLA through two separate transactions in 2015 and 2019. In accordance with our revenue recognition policy, ~~$6.4~~$7.1 million and ~~$15.5~~$13.5 million of non-cash royalties on net sales of KADCYLA were recorded and included in non-cash royalty revenue for the three and six months ended ~~March 31,~~June 30, 2022, respectively, compared to $16.7 million and $32.2 million in non-cash royalty revenue recorded for the three and six months ended June 30, 2021, respectively. The decrease in non-cash royalty revenue is a result of the aggregate royalty threshold, as outlined in the 2015 royalty purchase agreement, being met in the second quarter of 2021, effectively reducing the royalty payments under the 2015 transaction from 100% to 15% of KADCYLA royalty payments received over the remaining royalty term. Pursuant to the terms of these agreements, we expect to recognize less non-cash royalty revenue in 2022 and subsequent years as compared to 2021 and prior years. See further details regarding these agreements in Note F, “Liability Related to Sale of Future Royalties,” of the Consolidated Financial Statements.

Research and development expenses

Our research and development expenses relate to (i) research to evaluate new targets and to develop and evaluate new antibodies, linkers, and cytotoxic agents, (ii) preclinical testing of our own and, in certain instances, our collaborators’ product candidates, and the cost of our own clinical trials, (iii) development related to clinical and commercial manufacturing processes, (iv) regulatory activities, and (v) external manufacturing operations.

We do not track our research and development costs by project. Since we use our research and development resources across multiple research and development projects, we manage our research and development expenses within each of the categories listed in the following table and described in more detail below (in thousands):


	Six Months Ended						Six Months Ended
	June 30,				Increase/		June 30,						Increase/
Research and Development Expenses	2022		2021		(Decrease)		2022			2021			(Decrease)
Research	$	7,500	$	—	$	7,500		$	7,500		$	—		$	7,500
Preclinical and clinical testing		31,775		24,085		7,690			63,270			48,611			14,659
Process and product development		1,714		1,421		293			3,175			2,868			307
Manufacturing operations		10,433		9,083		1,350			21,759			17,523			4,236
Total research and development expenses	$	51,422	$	34,589	$	16,833		$	95,704		$	69,002		$	26,702

Three Months Ended


March 31,

Increase/
Research and Development Expenses


2022

2021

(Decrease)
Preclinical and clinical testing

$
31,495

$
24,526

6,969
Process and product development

1,461

1,447

14
Manufacturing operations

11,326

8,440

2,886
Total research and development expenses

$
44,282

$
34,413

$
9,869

~~Table of Contents~~

Research

Research includes expenses to evaluate new targets and to develop and evaluate new antibodies, linkers, and cytotoxic agents. Such expenses include third-party license fees, research funding payments, and contract services. Pursuant to a research collaboration agreement executed with OBT in June 2022, we recorded an upfront license fee as expense in the three and six months ended June 30, 2022. No similar expenses were recorded in the three and six months ended June 30, 2021.

Preclinical and clinical testing

Preclinical and clinical testing includes expenses related to preclinical testing of our own, and, in certain instances, our collaborators’ product candidates, regulatory activities, and the cost of clinical trials. Such expenses include the costs of personnel, third-party staffing, patient enrollment at our clinical testing sites, consultant fees, contract services, and facility expenses. In the three and six months ended ~~March 31,~~June 30, 2022, preclinical and clinical testing expenses increased by ~~$7.0~~$7.7 million and $14.7 million, respectively, compared to the three and six months ended ~~March 31,~~June 30, 2021, due primarily to ~~increased contract services,~~increases in personnel, third-party staffing costs, and ~~regulatory filing fees, particularly related to advancing MIRV.~~clinical trial costs driven by our MIRV and PVEK studies.

Process and product development

Process and product development expenses include costs for development of clinical and commercial manufacturing processes for our own and collaborator compounds. Such expenses include the costs of personnel, ~~third-party~~third-

Table of Contents

party staffing, contract services, and facility expenses. ~~Process and product development expenses were relatively flat for~~In each of the three and six months ended ~~March 31,~~June 30, 2022, preclinical and clinical testing expenses increased by $0.3 million compared to the three and six months ended ~~March 31, 2021.~~June 30, 2021, due primarily to increased personnel-related costs.

Manufacturing operations

Manufacturing operations expense includes costs to have preclinical and clinical materials manufactured for our product candidates and quality control and quality assurance activities. Such expenses include personnel, raw materials for our preclinical studies and clinical trials, non-pivotal and pivotal development costs with contract manufacturing organizations, and facility expenses. In the three and six months ended ~~March 31,~~June 30, 2022, manufacturing operations expense increased ~~$2.9~~by $1.4 million and $4.2 million, respectively, compared to the three and six months ended ~~March 31,~~June 30, 2021, due primarily to increases in personnel-related costs and external manufacturing activity across our programs.

Selling, general and administrative expenses

Selling, general and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for commercial operations and for personnel in executive, finance, accounting, business development, information technology, legal, and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, commercial development activities, legal fees related to intellectual property and corporate matters, and fees for accounting and consulting services.

~~Selling,~~In the three and six months ended June 30, 2022, selling, general and administrative expenses increased ~~$6.4~~by $14.1 million ~~to $16.6~~and $20.5 million, ~~in the three months ended March 31, 2022~~respectively, compared to the three and six months ended ~~March 31,~~June 30, 2021 due primarily ~~due~~ to building our commercial capabilities in anticipation of a potential U.S. launch of MIRV in the second half of 2022.

Non-cash interest expense on liability related to the sale of future royalties

In 2015, IRH purchased our right to receive 100% of the royalty payments on commercial sales of KADCYLA arising under our development and commercialization license with Genentech, subject to a residual cap. In January 2019, OMERS purchased IRH’s right to the royalties the Company previously sold in 2015. As described in Note E, “Liability Related to Sale of Future Royalties,” to our consolidated financial statements included in this report, this royalty sale transaction has been recorded as a liability that amortizes over the estimated royalty payment period as KADCYLA royalties are remitted directly to the purchaser. During the three and six months ended ~~March 31,~~June 30, 2022, ~~and 2021,~~ we recorded ~~$1.2~~$1.1 million and ~~$4.6~~$2.3 million ~~respectively,~~ of non-cash interest expense, respectively, which includes amortization of deferred financing ~~costs.~~costs, compared to $3.6 million and $8.2 million recorded in the three and six months ended June 30, 2021. The decrease was a result of a lower average royalty liability balance for the period and the KADCYLA royalty threshold being met in the second quarter of 2021, effectively reducing the royalty payments under the 2015 transaction from 100% to 15% of KADCYLA royalty payments received over the remaining royalty term.

LIQUIDITY AND CAPITAL RESOURCES

The tables below summarize our cash and cash equivalents, working capital, and shareholders’ equity as of ~~March 31,~~June 30, 2022 and December 31, 2021, and cash flow activities for the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021 (in thousands):


	As of
	June 30,		December 31,
	2022		2021
Cash and cash equivalents	$	373,874	$	478,750
Working capital		306,853		399,054
Shareholders’ equity		249,831		325,586


	Six Months Ended June 30,
	2022		2021
Cash used for operating activities	$	(105,393)		$	(88,500)
Cash used for investing activities		(514)			(940)
Cash provided by financing activities		1,031			35,122

Table of Contents

As of

March 31,

December 31,


2022

2021
Cash and cash equivalents

$
437,661

$
478,750
Working capital

372,600

399,054
Shareholders’ equity

306,468

325,586

Three Months Ended March 31,


2022

2021
Cash used for operating activities

$
(41,402)

$
(44,621)
Cash used for investing activities

(307)

(893)
Cash provided by financing activities

620

34,778

Cash flows

We require cash to fund our operating expenses, including the advancement of our clinical programs and to make capital expenditures. Historically, we have funded our cash requirements primarily through equity and convertible debt financings in private and public markets and payments from our collaborators, including license fees, milestone payments, research funding, and royalties. We have also monetized our rights to receive royalties on KADCYLA for upfront consideration. As of ~~March 31,~~June 30, 2022, we had ~~$437.7~~$373.9 million in cash and cash equivalents. Net cash used for operations was ~~$41.4~~$105.4 million and ~~$44.6~~$88.5 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021, respectively. The principal use of cash for operating activities for both periods presented was to fund our net loss, adjusted for non-cash items, with the ~~three~~six months ended ~~March 31,~~June 30, 2022 benefiting from a $13.0 million upfront payment pursuant to a license agreement with Lilly.

Net cash used for investing activities was ~~$0.3~~$0.5 million and $0.9 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021, respectively, consisting of cash outflows for capital expenditures in both periods, including computer and office equipment and dedicated equipment at third-party manufacturing vendors.

Net cash provided by financing activities was ~~$0.6~~$1.0 million and ~~$34.8~~$35.1 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021, respectively. Net cash provided by financing activities for the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021 includes ~~$0.6~~$1.0 million and ~~$1.3~~$1.7 million, respectively, of proceeds from the exercise of stock options. Additionally, in the ~~three~~six months ended ~~March 31,~~June 30, 2021, we sold 4,544,424 shares of our common stock under our Open Market Sale Agreement^SM (Sale Agreement) with Jefferies, LLC as sales agent, dated December 18, 2020, generating net proceeds of $33.5 million.

Future Capital Requirements

We have significant future capital requirements including:

●

significant expected operating expenses to conduct research and development activities and to potentially commercialize our portfolio;

●

noncancelable in-process and future manufacturing obligations; and

●

substantial facility lease obligations as described in Note H,J, “Leases,” included in our Annual Report on Form 10-K for the year ended December 31, 2021, and as described in Note G, “Leases,” included in this ~~report.~~Quarterly Report on Form 10-Q.

We anticipate that our current capital resources will enable us to meet our operational expenses and capital requirements for more than twelve months after the date of this report. We ~~may~~expect to raise additional funds through equity, debt, and other financings or generate revenues from ~~collaborators~~product sales as well as revenues from collaborations through a combination of upfront license payments, milestone payments, royalty payments, and research ~~funding.~~funding to support our planned operating activities. We cannot provide assurance, however, that we will be able to obtain additional debt, equity, or other financing or generate revenues from ~~collaborators~~product sales or from collaborations on terms acceptable to us or at all. Should we or our partners not meet some or all of the terms and conditions of our various collaboration agreements or if we are not successful in securing future collaboration agreements, we may elect or be required to secure alternative financing arrangements, and/or defer or limit some or all of our research, development, and/or clinical projects.

~~Table of Contents~~

Recent Accounting Pronouncements

The information set forth under Note B, “Summary of Significant Accounting Policies,” to our consolidated financial statements included in this report under the caption “Recently Adopted Accounting Pronouncements” is incorporated herein by reference.

Third-Party Trademarks

KADCYLA and AVASTIN are registered trademarks of Genentech, Inc. OGAP® is a registered trademark of Oxford BioTherapeutics Ltd.

Table of Contents

ITEM 3. Quantitative and Qualitative Disclosure about Market Risk

Our market risks, and the ways we manage them, are summarized in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022 and there have been no material changes to our market risks, or to our management of such risks, as set forth in such Annual Report on Form 10-K.

ITEM 4. Controls and Procedures

(a)	Disclosure Controls and Procedures

Our management, with the participation of our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, our principal executive and principal financial officers have concluded that, as of the end of such period, our disclosure controls and procedures were effective.

(b)	Changes in Internal Controls Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully review and consider the information regarding certain factors that could materially affect our business, financial condition, or future results set forth under Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 6, 2022. There have been no material changes from the factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 or Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, other than the ~~update to the~~ risk factor included below. We may, however, disclose changes to such risk factors, or disclose additional risk factors, from time to time in our future filings with the SEC.

~~Clinical trials~~Unfavorable global economic conditions could adversely affect our business, financial condition, and results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global economy has experienced extreme volatility and disruptions, including significant volatility in commodity and market prices, declines in consumer confidence, declines in economic growth, supply chain interruptions, uncertainty about economic stability, and inflation globally. Unfavorable economic conditions could result in a variety of risks to our business, including demand and pricing for our ~~product candidates and those of~~products, if approved, difficulty in forecasting our ~~collaborators will be lengthy and expensive, and their outcome is uncertain.~~

~~Before obtaining regulatory approval for the commercial sale of any product candidates, we~~financial results, and our ~~collaborators must demonstrate through clinical testing that~~ability to raise additional capital when needed and on acceptable terms. A weak or declining economy could also strain our ~~product candidates are safe~~suppliers, possibly resulting in supply chain disruptions. These and ~~effective for use in humans. Conducting clinical trials is a time-consuming, expensive,~~other economic factors could adversely affect our business and ~~uncertain process and typically requires years to complete. In our industry, the~~ results ~~from preclinical studies and early clinical trials often are not predictive~~ of results obtained in later-stage clinical trials. Some compounds that have shown promising results in preclinical studies or early clinical trials subsequently fail to establish sufficient safety and efficacy data necessary to obtain regulatory approval. For example, despite encouraging results from earlier clinical trials of mirvetuximab, operations.

our FORWARD I Phase 3 clinical trial evaluating mirvetuximab compared to chemotherapy in women with FRα-positive, platinum-resistant ovarian cancer, did not meet the primary endpoint in either the entire treatment population or the pre-specified high FRα expression population. Based on post hoc exploratory analyses of the FORWARD I results and consultations with the FDA, we implemented two new

~~Table of Contents~~

trials of mirvetuximab, SORAYA and MIRASOL, to support the potential approval of mirvetuximab as a monotherapy. We reported positive top-line data from our SORAYA trial, however, results from our ongoing MIRASOL study may not show positive results consistent with our SORAYA trial, post hoc exploratory analyses of the FORWARD I results, or earlier successful trials of mirvetuximab as monotherapy, which would cause significant harm to our business and future prospects.

Before we can commence clinical trials for a therapeutic candidate, we must conduct extensive preclinical testing and studies and submit an IND to FDA. We cannot be sure that submission of an IND will result in the FDA allowing our clinical trials to begin on the timelines we expect, if at all, as FDA may require additional preclinical, toxicology, or other ~~in vivo~~ or ~~in vitro~~ data to support the IND. Additionally, at any time during the clinical trials, we, our collaborators, or the FDA or other regulatory authority might delay or halt any clinical trials of our product candidates for various reasons, including:

●

~~occurrence of unacceptable toxicities or side effects;~~

●

~~ineffectiveness of the product candidate;~~

●

~~insufficient drug supply, including delays in obtaining supplies/materials necessary for manufacturing such drugs;~~

●

~~negative or inconclusive results from the clinical trials, or results that necessitate additional nonclinical studies or clinical trials;~~

●

~~delays in obtaining or maintaining required approvals from institutions, review boards, or other reviewing entities at clinical sites;~~

●

~~delays in patient enrollment;~~

●

~~insufficient funding or a reprioritization of financial or other resources;~~

●

our or our collaborators’ inability to develop and obtain approval for any companion in vitro diagnostic devices that the FDA or other regulatory authority may conclude must be used with such product candidates to ensure their safe use; or

●

~~other reasons that are internal to the businesses of our collaborators and third-party suppliers, which they may not share with us.~~

In addition, the conflict involving Russia and Ukraine has and may continue to negatively impact our contract research organizations and clinical investigators’ ability to conduct certain of our trials, including MIRASOL, in these and other Eastern European countries and may prevent us from obtaining data on patients already enrolled at sites in these countries. Any failure or substantial delay in successfully completing clinical trials and obtaining regulatory approval for our product candidates or our collaborators’ product candidates could severely harm our business.

Table of Contents

ITEM 6. Exhibits

Exhibit No.		Description
~~10.1~~3.1	*	~~License Agreement dated~~Restated Articles of Organization, as amended (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on April 30, 2010)
3.1(a)		Articles of ~~February 14, 2022~~Amendment (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on January 30, 2013)
3.1(b)		Articles of Amendment (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on August 4, 2017)
3.1(c)		Articles of Amendment (incorporated by reference to Exhibit 3.1(c) to the Registrant’s Quarterly Report on Form 10-Q filed on August 5, 2020)
3.1(d)		Articles of Amendment
10.1		Inducement Equity Incentive Plan, as amended
10.2		Amended and ~~between~~Restated 2018 Employee, Director and Consultant Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the ~~Registrant and Eli Lilly and Company~~Registrant’s Current Report on Form 8-K filed on June 17, 2022)
31.1		Certification of the principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of the principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32	†	Certifications of the principal executive officer and the principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101		Financial statements from the quarterly report on Form 10-Q of ImmunoGen, Inc. for the quarter ended ~~March 31,~~June 30, 2022 formatted in inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Operations and Comprehensive Loss; (iii) the Consolidated Statements of Shareholder’s Equity (Deficit); (iv) the Consolidated Statements of Cash Flows; and (v) the Notes to Consolidated Financial Statements
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*	~~Certain~~ confidential portions of this exhibit were omitted by means of marking such portions with brackets [***] because the identified confidential portions (i) are not material and (ii) is the type of information the Registrant treats as private or confidential.

†	Furnished, not filed.

2524

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ImmunoGen, Inc.

Date: ~~May 6,~~August 1, 2022	By:	/s/ Mark J. Enyedy
		Mark J. Enyedy
		President and Chief Executive Officer (Principal Executive Officer)

Date: ~~May 6,~~August 1, 2022	By:	/s/ Susan Altschuller, Ph.D.
		Susan Altschuller, Ph.D.
		Senior Vice President and Chief Financial Officer (Principal Financial Officer)

2625


2022 (nine months remaining)	$	4,114
2023		5,503
2024		5,522
2025		5,543
2026		1,429
Thereafter		13
Total lease payments		22,124
Less imputed interest		(4,099)
Total lease liabilities	$	18,025